Brief: Delcath Systems Announces FDA Acceptance Of NDA Resubmission Of Hepzato Kit
27/03/2023 13:27
March 27 (Reuters) - Delcath Systems Inc DCTH.O :
* DELCATH SYSTEMS, INC. ANNOUNCES FDA ACCEPTANCE OF NEW DRUG
APPLICATION RESUBMISSION OF HEPZATO KIT WITH A PDUFA DATE OF
AUGUST 14, 2023
Source text for Eikon: ID:nPn9ZHJQga
Further company coverage: DCTH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Delcath Systems
See all newsBrief: Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Delcath Systems Q1 revenue beats on Hepzato growth
Brief: Delcath Systems Announces Publication Of Chopin Clinical Trial Results In The Lancet Oncology
Delcath Q4 revenue rises 37%, beats estimates
Brief: Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)